复方α- 酮酸片治疗对糖尿病肾病患者肾功能及血清指标的影响

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy of Compound α-ketoacid Tablets on renal function and serum indexes in patients with diabetic nephropathy. Methods A total of 130 patients with diabetic nephropathy in the Third People′s Hospital Affiliated to Fujian University of Traditional Chinese Medicine from January 2018 to December 2020 were selected as subjects and divided into the test group and the control group according to random number table method,65 cases in each group. The control group received conventional treatment, and the test group was based on the control group, taking Compound α-ketoacid Tablets. Both groups were given treatment for 3 consecutive months. The changes of renal function index, renal interstitial fibrosis index and oxidative stress response index were compared between the two groups before and after treatment. Results After treatment, serum urea nitrogen (BUN), blood creatinine (Cr), homocysteine (Hcy), vascular endothelial growth factor (VEGF) and malondialdehyde (MDA) levels in the test group were lower than those in the control group, the differences were statistically significant (P<0.05). Serum levels of hepatocyte growth factor (HGF), total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) in the test group after treatment were higher than those in the control group, the differences were statistically significant (P<0.05). After treatment,the glomerular filtration rate (GFR) of the test group was faster than that of the control group, the difference was statistically significant (P<0.05). Conclusion Compound α-ketoacid Tablets can protect the renal function of patients with diabetic nephropathy, inhibit the occurrence of oxidative stress, and improve the indicators of renal interstitial fibrosis,and promote the improvement of the condition.

Key words： Diabetic nephropathy Compound α-ketoacid Tablets Renal function Oxidative stress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YOU Ping-ping
	KE Yuan-yuan
	XU Jia-qi
	DAI Lian▲

Cite this article:

YOU Ping-ping,KE Yuan-yuan,XU Jia-qi, et al. Efficacy of Compound α-ketoacid Tablets on renal function and serum indexes in patients with diabetic nephropathy[J]. 中国当代医药, 2021, 28(34): 116-119.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I34/116

[1]	张洪江，凃影叶，杜飞，等.TGF-β 参与糖尿病肾病的发生发展的机制研究现状[J].生命科学，2020，32（2）：85-93.
[2]	杜菲菲，马越.miR-155，miR-146a 在糖尿病肾病患者血清中的表达及诊断价值[J].中国医师杂志，2020，22（12）：1831-1835.
[3]	都静，张晓明.血清脂蛋白（α）及胱抑素C 与早期糖尿病肾病中医证型的相关性分析[J].西部中医药，2019，32（6）：1-3.
[4]	张晓利，胡威利.IGF-1R 抑制剂抑制糖尿病肾病小鼠肾脏纤维化[J].重庆医科大学学报，2020，45（3）：73-77.
[5]	郁越，孙伟.中西医结合方案治疗2 型糖尿病肾病Ⅳ期60例临床观察[J].中国中西医结合肾病杂志，2019，20（6）：540-541.
[6]	丁宏.海昆肾喜胶囊联合复方α-酮酸片治疗慢性肾功能衰竭的临床研究[J].现代药物与临床，2019，34（10）：3050-3054.
[7]	中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志，2021，37（3）：255-304.
[8]	冯祥田，于为民.糖尿病肾脏病与足细胞自噬[J].医学综述，2020，26（18）：154-159，165.
[9]	郑文，潘少康，刘东伟，等.糖尿病肾病治疗进展[J].中华肾脏病杂志，2020，36（6）：476-480.
[10]	付佳，徐琪，韩睿.维生素D 及其受体在糖尿病肾病发病中的研究进展[J].中国医药导报，2020，17（7）：23-26.
[11]	陈凯均，王欢，刁秀平.复方α-酮酸对维持性血液透析患者营养状态及微炎症的影响[J].海南医学，2019，30（14）：1791-1793.
[12]	林海涛.雷公藤多苷片加用复方α-酮酸片对糖尿病肾病患者肾功能及肾间质纤维化指标的影响[J].中国药物与临床，2019，19（14）：57-58.
[13]	林建美.雷公藤多苷片联合复方α-酮酸片对慢性肾衰竭患者的影响[J].中国医药导报，2019，16（24）：123-126.
[14]	周姝，董义军，白冰，等.尿毒清颗粒结合复方α-酮酸片对慢性肾衰竭肾功能及血清炎症因子的影响[J].中华中医药学刊，2020，38（11）：82-85.
[15]	冯立，彭博文，高智.百令胶囊联合α-酮酸片对慢性肾衰竭患者肾功能和微炎症状态的影响[J].现代中西医结合杂志，2019，2（3）：29-36.
[16]	黄丹，鞠梅，陈崑，等.α-硫辛酸对 UVB 诱导的角质形成细胞氧化应激的影响[J].中国麻风皮肤病杂志，2019，35（1）：1-5.
[17]	丁书红，石家绮，赵文娥，等.α-硫辛酸对黑素细胞氧化应激下的保护作用及抑制自噬机制的研究[J].临床皮肤科杂志，2019，5（6）：346-351.